bioMérieux – First-Quarter 2019 Business Review

• Organic growth of 3.8% (at constant exchange rates and scope of consolidation)
  • €632 million in sales
  • Up 7.7% as reported
• Growth led by the performance in molecular biology, during a first quarter shaped by a flu season of moderate intensity, and by strong sales momentum in the Asia Pacific region

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “Consolidated sales continued to grow in the first quarter of 2019. However, the growth rate was moderate, as expected, due primarily to a less intense flu season and a slower start to the year in Europe and in equipment sales. Today, we are confirming the annual objectives set for 2019.”

bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2019.

SALES

Consolidated sales amounted to €632 million in the first quarter of 2019, up from €587 million in the year-earlier period. As expected, sales growth at constant exchange rates and scope of consolidation was below the annual objective, at 3.8%, due to an unfavorable basis of comparison related to the flu season. Reported growth in euros came to 7.7%, reflecting a positive currency effect of €17 million driven by the rise in the US dollar, as well as the impact of changes in the scope of consolidation, which mainly correspond to the sales generated by Hybiome and Invisible Sentinel.